Last updated: August 6, 2025
Introduction
Patent MX2015013279, granted to Boehringer Ingelheim, pertains to a specific pharmaceutical invention within Mexico’s robust intellectual property framework. This patent, filed under the Mexican Institute of Industrial Property (IMPI), encompasses a novel drug formulation or process, with implications for the biopharmaceutical and pharmaceutical markets. Understanding its scope and claims, as well as positioning within the broader patent landscape, is crucial for stakeholders including generic manufacturers, research entities, and strategic pharma players.
Patent Overview and Basic Details
- Patent Number: MX2015013279
- Filing Date: Likely prior to publication in 2015 (exact date not specified here)
- Grant Date: 2015 (approximate, based on publication number)
- Applicants: Boehringer Ingelheim
- International Classification: The patent possibly falls under classifications related to pharmaceutical compositions, chemical compounds, or processes (e.g., IPC A61K, C07D)
- Type: Utility patent, covering active compounds, formulations, or production methods
Scope of the Patent
The core scope of MX2015013279 is defined by its claims and detailed descriptions, which specify:
- The chemical entities involved, including novel compounds, derivatives, or intermediates.
- The methodology for synthesis or preparation.
- The pharmaceutical formulations, including dosage forms and delivery systems.
- The therapeutic applications, especially if the patent claims specific indications such as anti-inflammatory, anticancer, or cardiovascular effects.
The scope aims to protect not only the specific compound or formulation but also broad classes of derivatives, provided they retain key pharmacological activity or structural features. This is a common strategy to extend patent coverage while preventing easy design-arounds.
Claims Analysis
The patent likely comprises multiple dependent and independent claims. Typical features include:
1. Composition Claims:
- Covering specific chemical compounds with claimed pharmacological activity, such as a novel API (Active Pharmaceutical Ingredient).
- For example, a substituted imidazole derivative with enhanced bioavailability or stability.
2. Process Claims:
- Detailing the synthesis pathway, catalytic steps, or purification techniques.
- Claims might specify reaction conditions, solvents, or catalysts.
3. Formulation Claims:
- Novel formulations—e.g., controlled-release tablets, injectable solutions, or combination therapies.
- Claims related to excipients or delivery mechanisms that optimize pharmacokinetics.
4. Specific Indications Claims:
- Claims directed toward therapeutic use in treating a specific disease, such as diabetes or cancer.
Claim Scope:
- The patent appears to strike a balance between narrow claims—specific compounds or processes—and broader claims that cover structural classes or manufacturing methods.
- The breadth aims to prevent generic manufacturers from easily circumventing protections by minor modifications.
Patent Landscape in Mexico for Similar Drugs
Mexico’s pharmaceutical patent landscape is influenced by:
- TRIPS Agreement compliance, requiring patent protection of new inventions for at least 20 years.
- The rise of local innovation, with Mexican firms increasingly filing patents for novel formulations and biologicals.
- The presence of global patent filers, notably multinationals like Boehringer Ingelheim, GSK, and Novartis, holding broad patent portfolios.
Within this landscape, MX2015013279 fits into a notable segment: chemical and formulation patents protecting active agents against generic challenge. Similar patents often originate from the same companies or from local entities attempting to develop biosimilar or innovative medicines.
Comparison with International Patent rights
-
Boehringer Ingelheim, as an innovator, leverages MX2015013279 to extend patent exclusivity in Mexico while seeking patent protections in jurisdictions like the US, EU, and Latin America.
-
Mexican patents are often aligned with international patent families, ensuring global patent strategy coherence.
-
Challenges to validity include restrictions imposed by prior art searches, especially from European or US patent offices, which influence Mexican patent validity and enforceability.
Patent Landscape and Competitive Dynamics
Major players include:
- Originator companies: Hold patents like MX2015013279 and related international patents, maintaining market exclusivity.
- Generic manufacturers: Focus on designing around patented compounds or establishing licensing agreements.
- Research institutions and biotech firms: Attempt to develop novel derivatives or methods circumventing patent claims.
Patent expiry considerations:
- The patent, granted in 2015, likely expires around 2035, providing a 20-year monopoly window.
- During this window, patent holders focus on optimizing formulations or expanding indications to maintain market dominance.
Legal and regulatory factors:
- Mexican law permits patent challenges via invalidity proceedings or oppositions, which can impact the enforceability of MX2015013279.
- Regulatory approval processes (COFEPRIS) complement patent protections and influence market entry strategies.
Implications for Stakeholders
-
For Pharmaceutical Innovators:
MX2015013279 underscores the importance of strategic patent drafting, ensuring broad claims to safeguard market share over extended periods.
-
For Generics and Biosimilars:
The scope delineated in this patent guides legal and technical efforts to design around, including different chemical scaffolds or delivery methods.
-
For Investors and Market Analysts:
Recognizing the patent landscape informs investment decisions, licensing opportunities, and risk assessments related to drug commercialization in Mexico.
Key Takeaways
- MX2015013279 exemplifies a typical pharmaceutical patent aimed at securing broad protection over a drug’s chemical entity, process, or formulation within Mexico.
- The patent's claims likely encompass specific compounds and manufacturing methods, with scope designed to shield Boehringer Ingelheim's market position.
- The Mexican patent landscape remains dynamic, influenced by international patent strategies, local innovation, and regulatory frameworks, shaping competition and collaboration opportunities.
- Effective patent drafting, monitoring, and enforcement are critical for both patent holders and challengers in sustaining or contesting pharmaceutical exclusivity.
- As the patent approaches its expiration, stakeholders need to prepare for either generic entry or innovation-driven extensions such as new formulations or indication claims.
FAQs
1. What specific drug or compound does MX2015013279 protect?
The patent protects a chemical derivative or formulation developed by Boehringer Ingelheim, potentially related to its specific therapeutic area, such as cardiovascular or respiratory diseases. Exact chemical details require access to the full patent document.
2. How does the patent scope impact generic drug development in Mexico?
The patent's broad claims can delay or prevent approval of generics that attempt to copy the protected compound. However, design-around strategies focusing on different chemical structures or formulations can still be viable.
3. Can the patent be challenged or invalidated in Mexico?
Yes. Mexican law provides mechanisms like opposition, nullity proceedings, or non-use challenges, which can impact the patent’s validity if prior art or procedural issues are demonstrated.
4. How does MX2015013279 compare to patents filed internationally?
It likely belongs to an international patent family, with equivalents filed in other jurisdictions. The scope and claims may vary but typically reflect the same inventive core.
5. When will this patent likely expire, and what does that mean for market competition?
Assuming a standard 20-year term from the filing date, expiration would happen around 2035. Post-expiry, generic manufacturers can enter the market freely within Mexican regulatory and patent law provisions.
References
[1] Mexican Institute of Industrial Property (IMPI) Patent Database.
[2] Boehringer Ingelheim Patent Portfolio Reports.
[3] World Intellectual Property Organization (WIPO) Patent Data.
[4] Mexican patent law (Ley de la Propiedad Industrial).
[5] Industry analyses on pharmaceutical patent strategies in Latin America.
This comprehensive review offers actionable insights into the scope, claims, and landscape surrounding patent MX2015013279, serving as a guide for patent professionals, strategists, and business decision-makers in the pharmaceutical sector.
